Shanghai Obio Technology (Group) Corp., Ltd. Class A
SSSE:6882386.50
CNY
-0.25
(-3.70%)
ISIN
CNE1000059N9
Return %
Stock
S&P 500
1Y
-15.47
14.20
3Y
-25.37
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Jun Yi Pan
- Full Time Employees
- 715
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Shanghai China
- IPO Date
- Mar 22, 2022
- Website
- obiosh.com
- Similar Companies
- Business
- Shanghai Obio Technology (Group) Corp., Ltd. is a China-based contract research organization (CRO) and contract development and manufacturing organization (CDMO) that provides comprehensive discovery, research, development, and biomanufacturing solutions for the global gene and cell therapy (GCT) industry. Founded in 2013 and headquartered in Shanghai, China, the company operates primarily across two core business segments: Gene Therapy CRO Services and Gene and Cell Therapy CDMO Services. The company's Gene Therapy CRO segment delivers basic scientific research and preclinical discovery services, including recombinant viral vector design, construction, and packaging across recombinant adeno-associated virus (rAAV), lentivirus (LV), adenovirus (ADV), retrovirus (RV), and herpes simplex virus (HSV) platforms; oncolytic virus screening and modification; functional genomics research; cell model engineering; disease model construction; and CRISPR/Cas9-mediated gene editing tools for academic institutions, hospital researchers, and biopharmaceutical discovery laboratories. The company's Gene and Cell Therapy CDMO segment offers end-to-end preclinical process development, clinical trial material supply, and commercial-scale manufacturing solutions, including plasmid DNA (pDNA) process development and cGMP production; clinical and commercial-grade viral vector manufacturing utilizing adherent and suspension bioreactor systems up to 2,000-liter scale; messenger RNA (mRNA) in vitro transcription, synthesis, and lipid nanoparticle (LNP) encapsulation services; autologous and allogeneic cell therapy manufacturing covering chimeric antigen receptor T-cell (CAR-T), T-cell receptor (TCR-T), chimeric antigen receptor natural killer (CAR-NK), tumor-infiltrating lymphocyte (TIL), and stem cell therapies; comprehensive analytical assay development, quality control testing, batch release, and stability studies; and global regulatory filing support for Investigational New Drug (IND) and Biologics License Applications (BLA). Shanghai Obio Technology serves biotechnology enterprises, pharmaceutical corporations, and biomedical research institutes across mainland China, North America, Europe, and the broader Asia-Pacific region. In recent operational developments, the company has fully commissioned and scaled production at its flagship commercial biomanufacturing facility, the Obio Smart Manufacturing Base located in the Lin-gang Special Area of Shanghai, adding approximately 77,000 square meters of facility space equipped with multiple dedicated plasmid lines, 11 viral vector production suites, and 12 cell therapy suites. Furthermore, the company has expanded its strategic alliances with domestic and international biopharmaceutical clients to support multi-regional IND filings with both the U.S. FDA and China NMPA, introduced upgraded high-yield AAV packaging and suspension cell platforms, and strengthened its global business development footprint to expand international CDMO service delivery.